Peptide biotech Parabilis targets up to $476M IPO at Gabrielle Masson

Location: Unknown.

Employment type: full-time.

Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing.